The new study included more than 120 men with metastatic castration-resistant prostate cancer, and was presented during the American Society of Clinical Oncology 2020 virtual meeting.
Altered mental state and stroke were the most common findings, which may help physicians better understand how the disease impacts the central nervous system.
The findings published Friday may help researchers develop new screening mechanisms to identify children who are at risk for the disorder and similar conditions.
Tauvid was developed by Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, and offers clinicians a new type of brain scan to use in patients being evaluated for Alzheimer's disease.